Pipeline

Codiak’s proprietary engEx™ platform for exosome engineering and manufacturing is enabling the development of potential therapies for diseases with high unmet needs. Using this breakthrough platform, we can produce exosomes that have precise and intentionally chosen properties and make them at industrial quality and scale.

engEx Therapeutic Pipeline

Codiak is developing a pipeline of engEx therapeutic candidates that may have a transformative impact for patients. We are exploring engineered exosomes in multiple indications, with an initial focus on oncology and neurology.

Oncology

exoIL-12™ CTCL Stage: Phase 1

Stage: Phase 1

Payload: Biologic

Dose route: Intratumoral

Phase 1 clinical trial began in September 2020

Exosome therapeutic candidate engineered using our engEx Platform to display IL-12 in a fully active form on the surface via Codiak’s novel protein scaffold, PTGFRN, which enables engagement of the IL-12 receptor on immune effector cells such as T- and NK-cells.

Learn more about exoIL-12™

exoSTING™ Solid tumors Stage: Phase 1

Stage: Phase 1

Payload: Small molecule

Dose route: Intratumoral

Phase 1/2 clinical trial began in September 2020.

Exosome therapeutic candidate engineered with our engEx Platform to carry Codiak’s proprietary STING (stimulator of interferon genes) agonist inside the lumen of the exosome while expressing high levels of PTGFRN, an exosomal protein, on the surface of the exosome to facilitate specific uptake in tumor-resident antigen presenting cells.

Learn more about exoSTING™

exoASO™-STAT6 Myeloid rich cancers (HCC) Stage: Phase 1

Stage: Phase 1

Payload: ASO

Dose route: Intravenous

Phase 1 trial expected to begin 1H 2022

Exosome therapeutic candidate engineered using our engEx Platform to overexpress PTGFRN to selectively target uptake in M2 polarized tumor-associated macrophages. Surface-loaded with an antisense oligonucleotide (ASO) targeting the STAT6 transcription factor, which acts as a potent switch of the polarization of the tumor-associated macrophages from an M2 tumor permissive/anti-inflammatory phenotype to an M1 T cell attracting, anti-tumor/inflammatory phenotype.

Learn more about exoASO™-STAT6

exoASO™-C/EBPB Myeloid rich cancers (NSCLC) Stage: Preclinical

Stage: Preclinical

Payload: ASO

Dose route: IV

Exosome therapeutic candidate engineered using our engEx Platform to selectively deliver antisense oligonucleotides (ASOs) to down-modulate C/EBPβ, a transcription factor that regulates the immunosuppressive phenotype in tumor-associated macrophages (TAMs) and circulating myeloid derived suppressor cells (MDSCs), two subpopulations of myeloid cells. High levels of C/EBPβ expression are associated with poor prognosis in multiple cancers, including non-small cell lung cancer (NSCLC). Precise targeting of C/EBPβ in MDSCs promotes the switch of TAMs from an M2 immunosuppressive phenotype to an M1, T cell attractive, anti-tumor phenotype and plays a key role in the survival and differentiation of MDSCs in order to induce an immune response.

Oncogene Targets Hematologic cancers / solid tumors Stage: Preclinical